Recombinant SARS-CoV-2 Omicron B.1.1.529 variant spike RBD protein

Référence 230-30201-10

Conditionnement : 10ug

Marque : RayBiotech

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Recombinant SARS-CoV-2 Omicron B.1.1.529 variant spike RBD protein

Recombinant SARS-CoV-2 Omicron variant spike S1 subunit protein RBD with 15 mutant sites (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) with C-terminal His-tag, derived from the transfected human HEK293 cells.
Contact Us for Bulk Request

Product Description

Specifications

Size10 µg
SpeciesSARS-CoV-2
Specificity
SARS-CoV-2 Omicron Variant B.1.1.529
Accession Number
QHD43416
Gene Symbols
S
Protein Name / Synonyms
Spike protein, S Protein, S1 Subunit, Host Cell Receptor Binding Domain (RBD)
Expressed Region
Arg319-Phe541. Omicron 15 mutant sites (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H)
Expression SystemHEK293 cells
TagC-terminal his-tag
Purity
>90%
Purity Determined BySDS-PAGE under reducing conditions and visualized by Coomassie blue staining
Molecular Weight (kDa)
Recombinant protein product has a calculated molecular mass of ∼25 kDa. Due to the abundant glycosylation, it migrates as approximately ∼30 kDa protein bands in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions. After deglycosylation under native and denature conditions, the protein presented as one reduced ∼25 kDa band.
Format
Liquid
Formulation
Supplied as a 0.2 µm filtered solution in PBS (pH 7.4)
Concentration (lot specific)
Lot specific (see the label on the vial), determined by BCA protein assay
Endotoxin Level< 0.5 EU per µg of the protein as determined by the LAL method
Research AreaInfectious Disease, COVID-19
Shipping TypeBlue ice
Storage-20°C
SDS-PAGE Image
SDS-PAGE image
Figure 1. Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.
Lane 1: protein standard ladder (kDa).
Lane 2: untreated protein.
Lane 3: treated protein with deglycosylation enzymes under native conditions.
Lane 4: treated protein with deglycosylation enzymes under denature conditions.

Stability & Storage

Storage/Stability
Upon arrival, the protein may be stored for 2 weeks at 4°C. For long term storage, it is recommended to store at -20°C or -80°C in appropriate aliquots. Avoid repeated freeze-thaw cycles.

Custom Labeling Request

We can custom label this protein with biotin or fluorescent dyes (choose from violet, blue, green or red). Request now.

citations

  • Pathogenicity of Sars-Cov-2 Spike Protein Variants Correlates with Coagulation and Complement Assays

    Year:
    2022
    Journal Name:
    Blood
  • Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273

    Year:
    2022
    Journal Name:
    Annals of Allergy Asthma & Immunology

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
CoV-Neut-P-100
 100uL